Psychosocial assessment in liver transplantation (LT): an analysis of short-term outcomes

• Published in: Hepatology communications Vol. 7; no. 1; p. e0017
• Main Authors: Matthews, Lindsay A, Musto, Jessica A, Deiss-Yehiely, Nimrod, Daniel, Kimberly E, Lightbourn, Christina, Garvey, Maureen, Osman, Fay, Foley, David P, Rice, John R, Lucey, Michael R
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01-01-2023; Wolters Kluwer Health/LWW
• Subjects: Biomarkers; End Stage Liver Disease - diagnosis; End Stage Liver Disease - surgery; Humans; Liver Diseases, Alcoholic; Liver Transplantation; Original; Retrospective Studies; Severity of Illness Index
• ISSN: 2471-254X; 2471-254X
• DOI: 10.1097/HC9.0000000000000017

Our research showed that patients with alcohol-associated liver disease (ALD) had more severe liver disease than those without a diagnosis of ALD yet were less likely to be selected for transplant listing due to their increased psychosocial vulnerability. This study aims to answer whether this vulnerability translates to worse short-term outcomes after transplant listing.
A total of 187 patients were approved for liver transplant listing and are included in the present retrospective study. We collected dates of transplantation, retransplantation, death, and pathologic data for evidence of rejection, and reviewed alcohol biomarkers and documentation for evidence of alcohol use.
The ALD cohort had higher Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) scores (39.4 vs. 22.5, p <0.001) and Model for End-Stage Liver Disease (MELD)-Na scores (25.0 vs. 18.5, p <0.001) compared with the non-ALD cohort. Forty-nine (59.7%) subjects with ALD and 60 (57.1%, p =0.71) subjects without ALD subsequently received a liver transplant. Overall mortality was similar between the 2 groups (20.7% ALD vs. 21.0% non-ALD, p =0.97). Neither the SIPAT score (HR: 0.98, 95% CI: 0.96-1.00, p =0.11) nor MELD-Na score (HR 0.99, 95% CI 0.95-1.02, p =0.40) were associated with mortality. Patients with ALD were more likely to have alcohol biomarkers tested both before (84.1% vs. 24.8% non-ALD, p <0.001) and after liver transplantation (74.0% vs. 16.7% non-ALD, p <0.001). SIPAT score was associated with alcohol use after listing (OR: 1.03, 95% CI: 1.0-1.07, p =0.04), although a return to alcohol use was not associated with mortality (HR: 1.60, 95% CI: 0.63-4.10, p =0.33).
Patients with ALD had higher psychosocial risk compared with patients without a diagnosis of ALD who were placed on the waitlist, but had similar short-term outcomes including mortality, transplantation, and rejection. Although a high SIPAT score was predictive of alcohol use, in the short-term, alcohol use after transplant listing was not associated with mortality.